Consensus recommendations for the diagnosis and management of hemophagocytic lymphohistiocytosis associated with malignancies
Standard
Consensus recommendations for the diagnosis and management of hemophagocytic lymphohistiocytosis associated with malignancies. / Lehmberg, Kai; Nichols, Kim E; Henter, Jan-Inge; Girschikofsky, Michael; Greenwood, Tatiana; Jordan, Michael; Kumar, Ashish; Minkov, Milen; La Rosée, Paul; Weitzman, Sheila; Study Group on Hemophagocytic Lymphohistiocytosis Subtypes of the Histiocyte Society.
In: HAEMATOLOGICA, Vol. 100, No. 8, 08.2015, p. 997-1004.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Consensus recommendations for the diagnosis and management of hemophagocytic lymphohistiocytosis associated with malignancies
AU - Lehmberg, Kai
AU - Nichols, Kim E
AU - Henter, Jan-Inge
AU - Girschikofsky, Michael
AU - Greenwood, Tatiana
AU - Jordan, Michael
AU - Kumar, Ashish
AU - Minkov, Milen
AU - La Rosée, Paul
AU - Weitzman, Sheila
AU - Study Group on Hemophagocytic Lymphohistiocytosis Subtypes of the Histiocyte Society
N1 - Copyright© Ferrata Storti Foundation.
PY - 2015/8
Y1 - 2015/8
N2 - The hyperinflammatory syndrome hemophagocytic lymphohistiocytosis can occur in the context of malignancies. Malignancy-triggered hemophagocytic lymphohistiocytosis should be regarded separately from hemophagocytic lymphohistiocytosis during chemotherapeutic treatment, which is frequently associated with an infectious trigger. The substantial overlap between the features of hemophagocytic lymphohistiocytosis with features of neoplasms makes its identification difficult when it occurs in malignant conditions. To facilitate recognition and diagnostic workup, and provide guidance regarding the treatment of malignancy-associated hemophagocytic lymphohistiocytosis, consensus recommendations were developed by the Study Group on Hemophagocytic Lymphohistiocytosis Subtypes of the Histiocyte Society, an interdisciplinary group consisting of pediatric and adult hemato-oncologists and immunologists.
AB - The hyperinflammatory syndrome hemophagocytic lymphohistiocytosis can occur in the context of malignancies. Malignancy-triggered hemophagocytic lymphohistiocytosis should be regarded separately from hemophagocytic lymphohistiocytosis during chemotherapeutic treatment, which is frequently associated with an infectious trigger. The substantial overlap between the features of hemophagocytic lymphohistiocytosis with features of neoplasms makes its identification difficult when it occurs in malignant conditions. To facilitate recognition and diagnostic workup, and provide guidance regarding the treatment of malignancy-associated hemophagocytic lymphohistiocytosis, consensus recommendations were developed by the Study Group on Hemophagocytic Lymphohistiocytosis Subtypes of the Histiocyte Society, an interdisciplinary group consisting of pediatric and adult hemato-oncologists and immunologists.
KW - Disease Management
KW - Humans
KW - Lymphohistiocytosis, Hemophagocytic
KW - Neoplasms
U2 - 10.3324/haematol.2015.123562
DO - 10.3324/haematol.2015.123562
M3 - SCORING: Journal article
C2 - 26314082
VL - 100
SP - 997
EP - 1004
JO - HAEMATOLOGICA
JF - HAEMATOLOGICA
SN - 0390-6078
IS - 8
ER -